New WHO Knowledge Portal Aims to End the Exclusion of Pregnant Women from Clinical Research
The World Health Organization and HRP have just launched a knowledge portal that addresses a gap we've all felt at the prenatal bedside: the near-total absence of pregnant and lactating women from clinical trial design.
For years you've likely seen the downstream effect in your own visits, where your clinician reaches for a medication or vaccine, and there's a pause, a careful line about limited data, and a conversation built mostly on extrapolation. The result is a familiar clinical reality: widespread off-label use, uncertainty at the pharmacy counter, and very little pregnancy-specific pharmacokinetic data behind decisions that affect both you and your baby.
WHO frames the launch as a direct response to that long-standing problem. Excluding pregnant and lactating women from research, the agency notes, does not eliminate risk; it simply shifts that risk into real-world settings where evidence is thinner and decision-making harder.
What the portal actually puts on the table
The resource is built primarily for the people designing trials: researchers, regulators, ethics committees, and product developers. The downstream effect should reach your exam room, too. WHO describes it as a curated hub of ethical, scientific, and operational materials intended to make responsible inclusion the default rather than the exception.
For you, the practical translation is straightforward. We can expect, over time, more trials designed with pregnancy and lactation in mind, clearer protocols for pharmacokinetics in the second and third trimesters, and more transparency around the off-label decisions that currently shape much of obstetric prescribing. That doesn't change what we do at your next visit, but it changes the conversation we can have with you in the years ahead.
What to ask at your next appointment
A useful next question to bring into your next prenatal or postpartum visit: when your clinician recommends a medication or vaccine, ask whether there's any pregnancy-specific safety data behind that recommendation, or whether the guidance is being extrapolated from non-pregnant populations. That single question reframes the default, signaling that you expect pregnancy-relevant evidence rather than a generic reassurance.
We'll be tracking how trial protocols, ethics submissions, and regulatory guidance start referencing this resource over the coming months, and what changes in the labelling decisions you actually see at the pharmacy counter.